Nicholas Borys

1.0k total citations
19 papers, 626 citations indexed

About

Nicholas Borys is a scholar working on Biomedical Engineering, Biomaterials and Reproductive Medicine. According to data from OpenAlex, Nicholas Borys has authored 19 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Biomedical Engineering, 5 papers in Biomaterials and 5 papers in Reproductive Medicine. Recurrent topics in Nicholas Borys's work include Ultrasound and Hyperthermia Applications (5 papers), Ovarian cancer diagnosis and treatment (5 papers) and Nanoparticle-Based Drug Delivery (5 papers). Nicholas Borys is often cited by papers focused on Ultrasound and Hyperthermia Applications (5 papers), Ovarian cancer diagnosis and treatment (5 papers) and Nanoparticle-Based Drug Delivery (5 papers). Nicholas Borys collaborates with scholars based in United States, China and Hong Kong. Nicholas Borys's co-authors include Ronnie T.P. Poon, Ronnie T. P. Poon, Mark W. Dewhirst, Ronald Van Heertum, K Jobst, Ronald A. Thisted, William Jagust, A. David Smith, Helen S. Mayberg and Michael D. Devous and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.

In The Last Decade

Nicholas Borys

19 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicholas Borys United States	8	310	281	148	99	99	19	626
Margaret F. Bennewitz United States	12	180 0.6×	173 0.6×	178 1.2×	74 0.7×	43 0.4×	29	762
Marzena Wylezinska‐Arridge United Kingdom	12	158 0.5×	122 0.4×	214 1.4×	33 0.3×	10 0.1×	19	682
Johannes Wölfer Germany	16	303 1.0×	98 0.3×	134 0.9×	50 0.5×	25 0.3×	37	938
Dechun Wang China	12	324 1.0×	61 0.2×	179 1.2×	55 0.6×	74 0.7×	27	702
Muyue Yang China	7	382 1.2×	191 0.7×	229 1.5×	17 0.2×	17 0.2×	13	837
Marc Schwarz Germany	13	246 0.8×	208 0.7×	125 0.8×	17 0.2×	21 0.2×	29	760
Kevin Fan United States	13	99 0.3×	57 0.2×	229 1.5×	31 0.3×	12 0.1×	15	680
Zongjun Zhang China	15	143 0.5×	101 0.4×	95 0.6×	11 0.1×	146 1.5×	33	842
Christopher O. McGovern United States	13	248 0.8×	119 0.4×	218 1.5×	25 0.3×	23 0.2×	20	680
Sarah Able United Kingdom	14	166 0.5×	109 0.4×	265 1.8×	26 0.3×	14 0.1×	22	585

Countries citing papers authored by Nicholas Borys

Since Specialization

Citations

This map shows the geographic impact of Nicholas Borys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Borys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Borys more than expected).

Fields of papers citing papers by Nicholas Borys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Borys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Borys. The network helps show where Nicholas Borys may publish in the future.

Co-authorship network of co-authors of Nicholas Borys

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Borys. A scholar is included among the top collaborators of Nicholas Borys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Borys. Nicholas Borys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Yin, Xiang, Elizabeth B. Lamont, Premal H. Thaker, et al.. (2023). Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. JCO Clinical Cancer Informatics. 7(7). e2200103–e2200103. 7 indexed citations

Thaker, Premal H., William H. Bradley, Charles A. Leath, et al.. (2021). GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. Clinical Cancer Research. 27(20). 5536–5545. 19 indexed citations

Borys, Nicholas & Mark W. Dewhirst. (2021). Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. Advanced Drug Delivery Reviews. 178. 113985–113985. 63 indexed citations

Thaker, Premal H., William H. Bradley, Charles A. Leath, et al.. (2019). Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer.. Journal of Clinical Oncology. 37(8_suppl). 2–2. 5 indexed citations

Thaker, Premal H., Nicholas Borys, Jason G. Fewell, & Khursheed Anwer. (2018). GEN-1 Immunotherapy for the Treatment of Ovarian Cancer. Future Oncology. 15(4). 421–438. 14 indexed citations

Thaker, Premal H., William H. Bradley, Charles A. Leath, et al.. (2017). Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). 5568–5568. 1 indexed citations

Kim, AeRang, Karun Sharma, Pavel Yarmolenko, et al.. (2017). Phase 1 trial of lyso-thermosensitive liposomal doxorubicin (LTLD) and magnetic resonance guided high intensity focused ultrasound (MR-HIFU) for pediatric refractory solid tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS10579–TPS10579. 5 indexed citations

Thaker, Premal H., William H. Bradley, Charles A. Leath, et al.. (2017). Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.. Journal of Clinical Oncology. 35(7_suppl). 155–155. 3 indexed citations

Thaker, Premal H., Charles A. Leath, William H. Bradley, et al.. (2016). Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.. Journal of Clinical Oncology. 34(15_suppl). TPS5605–TPS5605. 2 indexed citations

10.

Zagar, Timothy M., Željko Vujašković, Silvia C. Formenti, et al.. (2014). Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. International Journal of Hyperthermia. 30(5). 285–294. 92 indexed citations

11.

Sy, Park, M-H. Chen, Rui‐Hua Xu, et al.. (2014). Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm. 4 indexed citations

12.

Lencioni, Riccardo, Won Young Tak, Minhua Chen, et al.. (2014). Standardized radiofrequency ablation (sRFA) ≥ 45 minutes (m) plus lyso-thermosensitive liposomal doxorubicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: A retrospective analysis of phase III HEAT study.. Journal of Clinical Oncology. 32(15_suppl). e15143–e15143. 7 indexed citations

13.

Rugo, HS, et al.. (2013). Abstract P4-15-05: Novel targeted therapy for breast cancer chest wall recurrence: Low temperature liposomal doxorubicin and mild local hyperthermia. Cancer Research. 73(24_Supplement). P4–15. 1 indexed citations

14.

Poon, Ronnie T. P. & Nicholas Borys. (2011). Lyso-Thermosensitive Liposomal Doxorubicin: An Adjuvant to Increase The Cure Rate of Radiofrequency Ablation in Liver Cancer. Future Oncology. 7(8). 937–945. 79 indexed citations

15.

Borys, Nicholas, et al.. (2010). Initial Results of a Phase I/II Study Evaluating the Maximum Tolerated Dose, Pharmacokinetics, Safety, and Efficacy of Hyperthermia and Lyso-thermosensitive Liposomal (LTSL) Doxorubicin in Patients with Breast Cancer Recurrence at the Chest Wall (RCW). International Journal of Radiation Oncology*Biology*Physics. 78(3). S254–S255. 3 indexed citations

16.

Borys, Nicholas, et al.. (2010). Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of approved hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall.. Journal of Clinical Oncology. 28(15_suppl). TPS117–TPS117. 2 indexed citations

17.

Poon, Ronnie T.P. & Nicholas Borys. (2009). Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opinion on Pharmacotherapy. 10(2). 333–343. 155 indexed citations

18.

Jagust, William, Ronald A. Thisted, Michael D. Devous, et al.. (2001). SPECT perfusion imaging in the diagnosis of Alzheimer’s disease. Neurology. 56(7). 950–956. 162 indexed citations

19.

Harrison, Lynne, et al.. (1982). Dansyl Chloride: Relative Effect of Patch Testing Time. Journal of Toxicology Cutaneous and Ocular Toxicology. 1(4). 233–239. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact